TY  - JOUR
AU  - Thielmann, Carl Maximilian
AU  - Seier, Johanna Andrea
AU  - Schielke, Lisa
AU  - Albrecht, Lea Jessica
AU  - Zimmer, Lisa
AU  - Livingstone, Elisabeth
AU  - Zaremba, Anne
AU  - Lodde, Georg
AU  - Dissemond, Joachim
AU  - Sondermann, Wiebke
AU  - Krefting, Frederik
AU  - Tasdogan, Alpaslan
AU  - Roesch, Alexander
AU  - Hadaschik, Eva
AU  - Rambow, Florian
AU  - Griewank, Klaus
AU  - Ugurel, Selma
AU  - Schadendorf, Dirk
AU  - Placke, Jan-Malte
TI  - Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients.
JO  - Frontiers in immunology
VL  - 16
SN  - 1664-3224
CY  - Lausanne
PB  - Frontiers Media
M1  - DKFZ-2026-00028
SP  - 1727312
PY  - 2025
AB  - Checkpoint inhibition induced immune-related adverse events (irAE) may be steroid-dependent or steroid-refractory and are associated with increased morbidity, mortality and potentially compromised anti-tumor immunity. Extracorporeal photopheresis (ECP) has emerged as an alternative for salvage therapy, however, evidence remains scarce.This monocenter retrospective study included patients with either irColitis or irHepatitis, who received ECP after failure or dependence on high-dose corticosteroids + infliximab/vedolizumab or mycophenolate mofetil/tacrolimus. Clinical activity was quantified at least weekly (stool frequency for colitis; AST/ALT for hepatitis) and primary endpoint was change in irAE activity over time. Secondary analyses included steroid-sparing, overall safety, and melanoma-specific outcomes. Spearman's correlation assessed irAE severity reduction.Six patients were included in this study (irColitis n = 4; irHepatitis n = 2; CTCAE ≥ 3). Extracorporeal photopheresis was started after initial therapy with corticosteroids and immunosuppression was not successful. All ECP cycles included two consecutive treatment days. irAE activity declined promptly after ECP across patients: irColitis showed strong negative correlation with time since ECP (rs range -0.88 to -0.97); irHepatitis displayed parallel ALT/AST declines (rs ≥ -0.92). Corticosteroids were tapered following ECP start with a median corticosteroid reduction across all patients to 25
KW  - Humans
KW  - Photopheresis: methods
KW  - Male
KW  - Female
KW  - Middle Aged
KW  - Melanoma: drug therapy
KW  - Melanoma: immunology
KW  - Melanoma: therapy
KW  - Aged
KW  - Retrospective Studies
KW  - Immune Checkpoint Inhibitors: adverse effects
KW  - Immune Checkpoint Inhibitors: therapeutic use
KW  - Treatment Outcome
KW  - Programmed Cell Death 1 Receptor: antagonists & inhibitors
KW  - Programmed Cell Death 1 Receptor: immunology
KW  - Adult
KW  - extracorporeal photopheresis (Other)
KW  - immune checkpoint inhibitors (Other)
KW  - immune related colitis (Other)
KW  - immune related hepatitis (Other)
KW  - melanoma (Other)
KW  - Immune Checkpoint Inhibitors (NLM Chemicals)
KW  - Programmed Cell Death 1 Receptor (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:41476990
C2  - pmc:PMC12748251
DO  - DOI:10.3389/fimmu.2025.1727312
UR  - https://inrepo02.dkfz.de/record/307523
ER  -